

ENZO BIOCHEM INC  
Form 8-K  
July 07, 2015

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K**

**CURRENT REPORT Pursuant**

**to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of report (Date of earliest event reported): **July 2, 2015**

**Enzo Biochem, Inc.**

(Exact Name of Registrant as Specified in Its Charter)

**New York**

(State or Other Jurisdiction of Incorporation)

**001-09974**

**13-2866202**

(Commission File Number) (IRS Employer Identification No.)

**527 Madison Avenue**

**New York, New York** **10022**  
(Address of Principal Executive Offices) (Zip Code)

**(212) 583-0100**

(Registrant's Telephone Number, Including Area Code)

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions ( *see* General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

**Item 8.01 Other events**

On July 6, 2015, Enzo Biochem, Inc. (the “Company”) issued a press release announcing that on July 2, 2015, the Luminex Corporation agreed to pay the Company \$7.1 million in settlement of patent infringement litigation.

**Item 9.01. Financial Statements and Exhibits.**

**(d) Exhibits.**

- 99.1 Press Release of Enzo Biochem, Inc., dated July 6, 2015
- 99.2 Settlement and License Agreement between Enzo Life Sciences, Inc. and Luminex Corporation

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ENZO BIOCHEM, INC.

Date: July 7, 2015 By: /s/ Barry W. Weiner  
Barry W. Weiner  
President